These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

740 related articles for article (PubMed ID: 29330305)

  • 1. Restricted processing of CD16a/Fc γ receptor IIIa
    Patel KR; Roberts JT; Subedi GP; Barb AW
    J Biol Chem; 2018 Mar; 293(10):3477-3489. PubMed ID: 29330305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD16a with oligomannose-type
    Subedi GP; Barb AW
    J Biol Chem; 2018 Oct; 293(43):16842-16850. PubMed ID: 30213862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary Human Natural Killer Cells Retain Proinflammatory IgG1 at the Cell Surface and Express CD16a Glycoforms with Donor-dependent Variability.
    Patel KR; Nott JD; Barb AW
    Mol Cell Proteomics; 2019 Nov; 18(11):2178-2190. PubMed ID: 31467031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fc γ receptor IIIa/CD16a processing correlates with the expression of glycan-related genes in human natural killer cells.
    Patel KR; Rodriguez Benavente MC; Lorenz WW; Mace EM; Barb AW
    J Biol Chem; 2021; 296():100183. PubMed ID: 33310702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A single amino acid distorts the Fc γ receptor IIIb/CD16b structure upon binding immunoglobulin G1 and reduces affinity relative to CD16a.
    Roberts JT; Barb AW
    J Biol Chem; 2018 Dec; 293(51):19899-19908. PubMed ID: 30361439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Site-specific N-glycan Analysis of Antibody-binding Fc γ Receptors from Primary Human Monocytes.
    Roberts JT; Patel KR; Barb AW
    Mol Cell Proteomics; 2020 Feb; 19(2):362-374. PubMed ID: 31888963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody Fucosylation Lowers the FcγRIIIa/CD16a Affinity by Limiting the Conformations Sampled by the N162-Glycan.
    Falconer DJ; Subedi GP; Marcella AM; Barb AW
    ACS Chem Biol; 2018 Aug; 13(8):2179-2189. PubMed ID: 30016589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody receptors steal the sweet spotlight.
    Oliva KD; Cavanaugh JM; Cobb BA
    J Biol Chem; 2018 Mar; 293(10):3490-3491. PubMed ID: 29523693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allotype-specific processing of the CD16a N45-glycan from primary human natural killer cells and monocytes.
    Patel KR; Roberts JT; Barb AW
    Glycobiology; 2020 Jul; 30(7):427-432. PubMed ID: 31967297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of N-Glycan Composition on Structure and Dynamics of IgG1 Fc and Their Implications for Antibody Engineering.
    Lee HS; Im W
    Sci Rep; 2017 Oct; 7(1):12659. PubMed ID: 28978918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibiting N-glycan processing increases the antibody binding affinity and effector function of human natural killer cells.
    Rodriguez Benavente MC; Hughes HB; Kremer PG; Subedi GP; Barb AW
    Immunology; 2023 Oct; 170(2):202-213. PubMed ID: 37218360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The weaker-binding Fc γ receptor IIIa F158 allotype retains sensitivity to N-glycan composition and exhibits a destabilized antibody-binding interface.
    Kremer PG; Barb AW
    J Biol Chem; 2022 Sep; 298(9):102329. PubMed ID: 35921896
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-targeted characterization of attributes affecting antibody-FcγRIIIa V158 (CD16a) binding via online affinity chromatography-mass spectrometry.
    Woodall DW; Dillon TM; Kalenian K; Padaki R; Kuhns S; Semin DJ; Bondarenko PV
    MAbs; 2022; 14(1):2004982. PubMed ID: 34978527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of a Recombinant High Affinity IgG Fc Receptor by Engineered NK Cells as a Docking Platform for Therapeutic mAbs to Target Cancer Cells.
    Snyder KM; Hullsiek R; Mishra HK; Mendez DC; Li Y; Rogich A; Kaufman DS; Wu J; Walcheck B
    Front Immunol; 2018; 9():2873. PubMed ID: 30574146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The immunoglobulin G1 N-glycan composition affects binding to each low affinity Fc γ receptor.
    Subedi GP; Barb AW
    MAbs; 2016; 8(8):1512-1524. PubMed ID: 27492264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined Fc-protein- and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCC.
    Repp R; Kellner C; Muskulus A; Staudinger M; Nodehi SM; Glorius P; Akramiene D; Dechant M; Fey GH; van Berkel PH; van de Winkel JG; Parren PW; Valerius T; Gramatzki M; Peipp M
    J Immunol Methods; 2011 Oct; 373(1-2):67-78. PubMed ID: 21855548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Engineering the fragment crystallizable (Fc) region of human IgG1 multimers and monomers to fine-tune interactions with sialic acid-dependent receptors.
    Blundell PA; Le NPL; Allen J; Watanabe Y; Pleass RJ
    J Biol Chem; 2017 Aug; 292(31):12994-13007. PubMed ID: 28620050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carbohydrate-Polypeptide Contacts in the Antibody Receptor CD16A Identified through Solution NMR Spectroscopy.
    Subedi GP; Falconer DJ; Barb AW
    Biochemistry; 2017 Jun; 56(25):3174-3177. PubMed ID: 28613884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Control of recombinant monoclonal antibody effector functions by Fc N-glycan remodeling in vitro.
    Hodoniczky J; Zheng YZ; James DC
    Biotechnol Prog; 2005; 21(6):1644-52. PubMed ID: 16321047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. One N-glycan regulates natural killer cell antibody-dependent cell-mediated cytotoxicity and modulates Fc γ receptor IIIa / CD16a structure.
    Kremer PG; Lampros EA; Blocker AM; Barb AW
    bioRxiv; 2024 Aug; ():. PubMed ID: 38948809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.